Tango Therapeutics Q3 Earnings Fall Short of Expectations
Monday, 18 March 2024, 11:11
Tango Therapeutics Q3 Financial Performance
Tango Therapeutics reported a GAAP EPS of -$0.32, missing estimates by $0.04, and revenue of $5.43M, falling short by $2.81M. The disappointing results have sparked discussions about the company's future direction.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.